Capricor Therapeutics Provides Update on ALLSTAR Trial

Unlikely to Achieve Primary Efficacy Endpoint of Change in Infarct Size in Patients Following Heart Attack Capricor to Focus on Potential Registration Program in Duchenne Muscular Dystrophy Company to Hold Conference Call Today at 5:00 AM PDT / 8:00 ... Regenerative Medicine, Cardiology Capricor Therapeutics, ALLSTAR Trial, allogeneic cardiosphere-derived cells
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news